Cutia Therapeutics's latest marketcap:
As of 07/26/2025, Cutia Therapeutics's market capitalization has reached $372.44 M. According to our data, Cutia Therapeutics is the 16427th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 372.44 M |
| Revenue (ttm) | 37.91 M |
| Net Income (ttm) | -58,814,866.09 |
| Shares Out | 318.1 M |
| EPS (ttm) | -0.19 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/29/2025 |
Cutia Therapeutics's yearly market capitalization.
| Date | Market Cap(HK$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/26/2025 | HK$2.92 B | $372.44 M | 29.18% | 16427 |
| 12/31/2024 | HK$2.26 B | $290.23 M | -32.43% | 16636 |
| 12/29/2023 | HK$3.34 B | $427.35 M | 14028 |
Company Profile
About Cutia Therapeutics
Cutia Therapeutics is an investment holding company specializing in the research, development, manufacture, and commercialization of innovative dermatological and skincare products. Headquartered in Shanghai, China, the company operates primarily in the People’s Republic of China and Hong Kong.
Core Focus Areas
Cutia Therapeutics concentrates on dermatology treatment and care, with key therapeutic areas including:
- Localized adipose accumulation management
- Scalp diseases and care
- Skin diseases and care
- Topical anesthesia
Key Products
- CU-40102: A topical finasteride spray approved for treating androgenetic alopecia.
- CU-10201: A topical 4% minocycline foam approved for acne vulgaris treatment.
- CU-10101: A non-hormonal small molecule agent for mild to moderate atopic dermatitis.
Pipeline Developments
- CU-20401: A recombinant mutant collagenase in Phase II trials for submental fat reduction.
- CU-40101: A topical thyroid hormone receptor agonist (Phase I completed) for androgenetic alopecia.
- CU-30101: A lidocaine-tetracaine compound cream (Phase III completed) for dermatologic procedures.
Founded in 2019, Cutia Therapeutics continues to advance its portfolio of dermatological solutions to address unmet medical needs.
Frequently Asked Questions
-
What is Cutia Therapeutics's (HKG-2487) current market cap?As of 07/26/2025, Cutia Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $372.44 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Cutia Therapeutics (HKG-2487) rank globally by market cap?Cutia Therapeutics global market capitalization ranking is approximately 16427 as of 07/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.